| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3889929 | Kidney International | 2006 | 4 Pages |
Abstract
Serum parathyroid hormone (PTH) is a recognized marker of bone remodeling in patients with renal osteodystrophy. However, identification of N-terminal truncated PTH fragments and a new form of PTH that interfere with second-generation PTH assays may be responsible for the great variability of PTH values and the difficulties of implementing the recommendations of the National Kidney Foundation/Kidney Disease Outcomes Quality Initiative.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
P. Ureña Torres,